CONCLUSION
The following conclusions can be drawn from the results obtained from
our study. Ropivacaine 0.75%
provides significantly longer duration of anesthesia than lignocaine 2%
with adrenaline. Ropivacaine 0.75% decreases the intraoperative and
postoperative analgesia compared to lignocaine 2% with adrenaline.
Thus, efficacy of ropivacaine 0.75% is superior to lignocaine 2% with
1:200,000 adrenaline in terms of duration of anesthesia and analgesia.
Hence, ropivacaine 0.75% can be used as an alternative to lignocaine in
implant surgeries and other surgical procedures which require longer
duration of anesthesia and analgesia intraorally. Moreover, ropivacaine
0.75% can be used safely in patients in whom adrenaline use has to be
minimized. No adverse effects were reported with ropivacaine in our
study. Further studies are required to evaluate the safety and efficacy
of ropivacaine in medically compromised patients undergoing implant and
periodontal surgeries.